Testing effectiveness (Phase 2)Ended earlyNCT00740181What this trial is testingDecitabine, Cytarabine, GCSF for Refractory AML/MDSWho this might be right forMyelodysplasiaLeukemia Brown University 9
Testing effectiveness (Phase 2)Active Not RecruitingNCT04128748What this trial is testingLiposomal Cytarabine and Daunorubicin (CPX-351) and Quizartinib for the Treatment of Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeWho this might be right forAcute Myeloid LeukemiaBlasts More Than 10 Percent of Bone Marrow Nucleated CellsHigh Risk Myelodysplastic Syndrome+4 more M.D. Anderson Cancer Center 52
Early research (Phase 1)Ended earlyNCT02749708What this trial is testingStudy of IRX5183 in Relapsed and Refractory Acute Myeloid Leukemia and High Risk Myelodysplastic SyndromeWho this might be right forAcute Myeloid Leukemia (AML)Myelodysplastic Syndrome (MDS)Chronic Myelomonocytic Leukemia (CMML) Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 13
Testing effectiveness (Phase 2)Ended earlyNCT01118013What this trial is testingDonor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Malignancies or Secondary Myelodysplasia Previously Treated With High-Dose Chemotherapy and Autologous Stem Cell TransplantWho this might be right forLeukemiaLymphomaLymphoproliferative Disorder+3 more Alliance for Clinical Trials in Oncology 6
Testing effectiveness (Phase 2)Study completedNCT02197676What this trial is testingA Phase II Trial of SGI-110 in Patients With IPSS High and Int 2 Myelodysplastic Syndrome, Acute Myeloid Leukemia With 20-30% Marrow Blasts or Chronic Myelomonocytic Leukemia Type 2 Not Responding to Azacitidine or Decitabine After at Least 6 Courses or Relapsing After a ResponseWho this might be right forMDS Groupe Francophone des Myelodysplasies 56
Testing effectiveness (Phase 2)Ended earlyNCT05918055What this trial is testingEltanexor (KPT-8602) With Inqovi (Decitabine-Cedazuridine) in High-Risk Myelodysplastic SyndromesWho this might be right forMyelodysplastic Syndromes National Cancer Institute (NCI) 3
Testing effectiveness (Phase 2)Study completedNCT02018926What this trial is testingSafety Study of Mocetinostat in Combination With Azacitidine in Subjects With MDSWho this might be right forMyelodysplastic Syndrome Mirati Therapeutics Inc. 18
Early research (Phase 1)Study completedNCT00077558What this trial is testing3-AP Followed By Fludarabine In Treating Patients With Relapsed or Refractory Acute or Chronic Leukemia or High-Risk Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic SyndromesMyelodysplastic/Myeloproliferative Diseases Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Testing effectiveness (Phase 2)Ended earlyNCT01442714What this trial is testingAzacitidine + Lenalidomide Combo in the Elderly With Previously Treated AML & High-Risk MDSWho this might be right forLeukemiaAcute Myeloid Leukemia (AML)Myelodysplastic Syndromes (MDS) Stanford University 33
Testing effectiveness (Phase 2)Study completedNCT02286726What this trial is testingCPX-351 in Treating Patients With Newly Diagnosed, High-Risk Acute Myeloid LeukemiaWho this might be right forAcute Myeloid LeukemiaAcute Myeloid Leukemia Arising From Previous Myelodysplastic SyndromeSecondary Acute Myeloid Leukemia M.D. Anderson Cancer Center 56
Testing effectiveness (Phase 2)Looking for participantsNCT05732103What this trial is testingCTX-712 in Relapsed/Refractory Acute Myeloid Leukemia and Higher Risk Myelodysplastic SyndromesWho this might be right forAcute Myeloid LeukemiaMyelodysplastic Syndromes Chordia Therapeutics, Inc. 225
Early research (Phase 1)Study completedNCT04402541What this trial is testingStudy of CB-5339 in Acute Myeloid Leukemia or Myelodysplastic SyndromeWho this might be right forAcute Myeloid Leukemia, in RelapseMyelodysplastic Syndromes Cleave Therapeutics, Inc. 55
Testing effectiveness (Phase 2)Study completedNCT00077116What this trial is testingIdarubicin, Cytarabine, and Gemtuzumab Ozogamicin in Treating Patients With Previously Untreated High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Secondary to Myelodysplastic SyndromeWho this might be right forLeukemiaMyelodysplastic Syndromes European Organisation for Research and Treatment of Cancer - EORTC 31
Testing effectiveness (Phase 2)Study completedNCT01085838What this trial is testingErlotinib in Higher Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndrome Groupe Francophone des Myelodysplasies 30
Testing effectiveness (Phase 2)Study completedNCT00394381What this trial is testingAutologous Cytokine-induced Killer Cell Adoptive Immunotherapy for Acute Myeloid Leukemia and Myelodysplastic SyndromeWho this might be right forAcute Myeloid LeukemiaMyelodysplastic Syndrome, High Grade Singapore General Hospital 17
Not applicableUnknownNCT06279338What this trial is testingA Novel Conditioning Regimen for Myelodysplastic Syndrome With Moderate High IPSS-M ScoreWho this might be right forMyelodysplastic Syndromes Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 40
Early research (Phase 1)Study completedNCT00374933What this trial is testingEnhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell TransplantationWho this might be right forAcute Myelogenous LeukemiaAcute Lymphoblastic LeukemiaMyelodysplastic Syndrome Abramson Cancer Center at Penn Medicine 18
Testing effectiveness (Phase 2)Ended earlyNCT01880437What this trial is testingVismodegib in Patients With Relapsed/Refractory Acute Myelogenous Leukemia and Relapsed Refractory High-Risk Myelodysplastic SyndromeWho this might be right forMyelodysplastic Syndromes, Myelogenous Leukemia, Acute Hoffmann-La Roche 38
Testing effectiveness (Phase 2)Study completedNCT00010283What this trial is testingBeclomethasone in Treating Patients With Graft-Versus-Host Disease of the Esophagus, Stomach, Small Intestine, or ColonWho this might be right forBreast CancerChronic Myeloproliferative DisordersGestational Trophoblastic Tumor+9 more Fred Hutchinson Cancer Center
Not applicableStudy completedNCT00789256What this trial is testingLow Dose Melphalan and Bortezomib for AML and High-Risk MDSWho this might be right forAcute Myelogenous LeukemiaMyelodysplastic Syndromes Dartmouth-Hitchcock Medical Center 26